"Antibodies, Neutralizing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
Below are MeSH descriptors whose meaning is more general than "Antibodies, Neutralizing".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Neutralizing".
This graph shows the total number of publications written about "Antibodies, Neutralizing" by people in this website by year, and whether "Antibodies, Neutralizing" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Neutralizing" by people in Profiles.
HSV-1 0?NLS vaccine elicits a robust B lymphocyte response and preserves vision without HSV-1 glycoprotein M or thymidine kinase recognition. Sci Rep. 2022 09 23; 12(1):15920.
Severe Acute Respiratory Syndrome Coronavirus 2 Viremia Is Associated With Coronavirus Disease 2019 Severity and Predicts Clinical Outcomes. Clin Infect Dis. 2022 05 03; 74(9):1525-1533.
Induction of broadly reactive influenza antibodies increases susceptibility to autoimmunity. Cell Rep. 2022 03 08; 38(10):110482.
Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer. Lancet. 2022 03 05; 399(10328):905-907.
Hydrogen-Deuterium Exchange Mass Spectrometry Reveals a Novel Binding Region of a Neutralizing Fully Human Monoclonal Antibody to Anthrax Protective Antigen. Toxins (Basel). 2022 01 25; 14(2).
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. Cancer Cell. 2022 02 14; 40(2):114-116.
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study. Nat Cancer. 2021 12; 2:1321-1337.
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nat Cancer. 2021 12; 2(12):1305-1320.
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nat Cancer. 2021 12; 2(12):1321-1337.
Intranasal and intrapulmonary vaccination with an M protein-deficient respiratory syncytial virus (RSV) vaccine improves clinical signs and reduces viral replication in infant baboons after an RSV challenge infection. Vaccine. 2021 07 05; 39(30):4063-4071.